Anemia after renal transplantation

被引:69
作者
Afzali, Behdad
Al-Khoury, Salam
Shah, Nilesh
Mikhail, Ashraf
Covic, Adrian
Goldsmith, David
机构
[1] Guys Hosp, Renal Unit, Dept Nephrol & Transplantat, London SE1 9RT, England
[2] Morriston Hosp, Renal Unit, Swansea, W Glam, Wales
[3] Parhon Hosp, Iasi, Romania
基金
英国医学研究理事会;
关键词
anemia; renal transplant; renal function; immunosuppression; erythropoiesis-stimulating agents;
D O I
10.1053/j.ajkd.2006.07.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Anemia in the setting of chronic kidney disease is a well-recognized phenomenon that is associated with decreasing renal function and deficiency of or resistance to erythropoietin. However, anemia in the post-renal transplantation setting has received comparatively less attention in the literature. In this review, we aim critically to appraise the available literature regarding posttransplantation anemia, concentrating in particular on the prevalence of posttransplantation anemia, its etiopathogenesis, potential effects on morbidity and mortality, and the rationale for intervention and treatment. Despite deficiencies in the literature, we conclude that posttransplantation anemia is a common phenomenon that can occur either early or late posttransplantation, and its causation is usually multifactorial and includes contributions notably from poor or decreasing renal function, immunosuppression, and iron deficiency. Conversely, there is a shortage of well-conducted prospective studies looking at the morbidity attributable to posttransplantation anemia and a lack of trial evidence to determine whether intervention improves patient morbidity and outcome.
引用
收藏
页码:519 / 536
页数:18
相关论文
共 106 条
[1]   Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy [J].
Aftali, B ;
Shah, S ;
Chowdhury, P ;
O'Sullivan, H ;
Taylor, J ;
Goldsmith, D .
TRANSPLANTATION, 2005, 79 (03) :304-309
[2]   What we CAN do about chronic allograft nephropathy: Role of immunosuppressive modulations [J].
Afzali, B ;
Taylor, AL ;
Goldsmith, DJA .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2429-2443
[3]  
Afzali B, 2004, J NEPHROL, V17, P487
[4]   Azathioprine-induced pure red cell aplasia: Case report and review [J].
Agrawal, A ;
Parrott, NR ;
Riad, HN ;
Augustine, T .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (09) :2689-2691
[5]   Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis [J].
Al-Uzri, A ;
Yorgin, PD ;
Kling, PJ .
PEDIATRIC TRANSPLANTATION, 2003, 7 (04) :253-264
[6]   Microangiopathic hemolytic anemia secondary to cyclosporine [J].
Alonso-Santor, JE ;
Gutierrez-Zufiaurre, JL ;
Pérez-Castrillón, JL .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) :903-903
[7]   Chronic cyclosporine nephrotoxicity [J].
Andoh, TF ;
Bennett, WM .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (03) :265-270
[8]  
[Anonymous], 2001, Am J Kidney Dis, V37, pS182
[9]  
[Anonymous], 1968, WHO TECHN REP SER
[10]   Reproducible erythroid aplasia caused by mycophenolate mofetil [J].
Arbeiter, K ;
Greenbaum, L ;
Balzar, E ;
Müller, T ;
Hofmeister, F ;
Bidmon, B ;
Aufricht, C .
PEDIATRIC NEPHROLOGY, 2000, 14 (03) :195-197